**Research-use only.** This product is a constituted research-grade reference-standard solution supplied by Coastal Vanguard LLC for laboratory research, in-vitro investigation, analytical-method development, and preclinical research conducted by qualified researchers. It is not a medication, is not approved by the U.S. Food and Drug Administration, the European Medicines Agency, or any other regulatory authority for human or veterinary administration, and is supplied strictly under a research-use-only label.
**Molecule:** Retatrutide — a synthetic triple-agonist peptide analog under investigation in research settings for receptor pharmacology at the GLP-1, GIP, and glucagon receptors.
**Format:** Preloaded research pen, multi-dose options from 8 mg to 48 mg.
**Purity:** ≥99% HPLC, mass-spectrometry identity confirmed.
**What this product is:** A constituted research-grade reference-standard solution sealed in a sterile vial with a lot-specific Certificate of Analysis.
**What this product is not:** A medication, a supplement, a diagnostic, a treatment, or a therapeutic for any human or veterinary condition. It is not intended for administration to humans or animals.
**Intended use:** Laboratory research, in-vitro assays, analytical-method development (HPLC, mass spectrometry), receptor-pharmacology studies, and preclinical research conducted under appropriate institutional oversight.
**Storage and handling:** Store at 2–8 °C / 36–46 °F (short-term) or −20 °C / −4 °F (long-term). Use within 30 days of first puncture. Refer to the Certificate of Analysis for lot-specific purity, residual solvent, and endotoxin data.